All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Early stage vaccine developer Osivax SAS raised €8 million (U$9 million) in series A funding to continue development of a clinical-stage universal influenza vaccine, based on what it believes is a highly immunogenic method of presenting the viral nucleoprotein to the immune system.